Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOLAIR-SR vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and antagonizing adenosine receptors.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of symptoms and prevention of asthma,Treatment of chronic bronchitis and emphysema (COPD),Apnea of prematurity (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/m L).
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Adults: 8 hours (range 5-12). Children: 3.5 hours (range 1-8). Smokers: 4-5 hours. Congestive heart failure/hepatic cirrhosis: >24 hours.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily metabolized by hepatic CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Extensive first-pass metabolism. Metabolites excreted renally.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal (10% unchanged) and hepatic metabolism (90%). Metabolites excreted in urine.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
40% bound, primarily to albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
0.45 L/kg. Distributes into total body water; higher in premature infants and patients with cirrhosis.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral (extended-release): 96-100%.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No specific GFR-based dose adjustment required; use with caution in renal impairment due to altered clearance; monitor serum concentrations.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh Class A: Reduce dose by 50%. Child-Pugh Class B: Reduce dose by 50% and monitor closely. Child-Pugh Class C: Consider alternative therapy; if used, reduce dose by 75% with frequent monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Children >1 year: Initial 16 mg/kg/day or 400 mg/day (whichever is less) divided every 12 hours; maximum dose: 24 mg/kg/day (not to exceed 900 mg/day). Target serum concentration 5-15 mcg/m L.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Over 60 years: Lower initial dose (e.g., 300 mg/day) due to decreased clearance; titrate slowly; monitor serum theophylline concentrations closely to avoid toxicity.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Dose-related adverse effects include seizures and arrhythmias.
None.
Risk of seizure and arrhythmia at toxic levels; monitor serum theophylline concentrations closely. Use with caution in patients with heart failure, hepatic impairment, chronic alcoholism, and viral infections. Interactions with drugs affecting CYP1A2 (e.g., ciprofloxacin, fluvoxamine, smoking cessation) require dose adjustment.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or any component of the formulation. Patients with pre-existing cardiac arrhythmias (e.g., atrial fibrillation, ventricular tachycardia) unless controlled. History of seizure disorder (use only if benefits outweigh risks).
Hypersensitivity to theophylline or any component of the formulation.
High-fat meals may increase absorption; avoid drastic dietary changes. Concurrent caffeine intake can increase theophylline effects and toxicity risk. Charcoal-broiled foods and a high-protein diet may decrease theophylline levels. Grapefruit juice may increase theophylline levels (moderate interaction).
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Theophylline crosses the placenta. First trimester: No clear evidence of major malformations in human studies, but animal studies show some risk at high doses (skeletal variations). Second trimester: No specific risks; use if benefit outweighs risk. Third trimester: Fetal tachycardia, jitteriness, and withdrawal symptoms (irritability, vomiting) in neonates due to transplacental accumulation. Avoid near term if possible.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline is excreted into breast milk. Milk/plasma ratio approximately 0.6-0.7. Infant exposure is about 1-10% of maternal weight-adjusted dose, leading to potentially therapeutic or toxic levels in infant serum. Possible effects include irritability, insomnia, and feeding intolerance. Use with caution; monitor infant for adverse effects.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Significant pharmacokinetic changes: increased clearance due to hepatic induction and increased renal excretion; decreased protein binding. May require dose increase. Monitor serum concentrations frequently (every 2-4 weeks) and adjust to maintain therapeutic levels (5-15 mcg/m L). Postpartum, clearance decreases; reduce dose to prevent toxicity.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Theolair-SR is a sustained-release theophylline formulation. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L) to avoid toxicity, especially in patients with hepatic impairment or those on interacting drugs. Tachyphylaxis may occur with chronic use. Caution in patients with peptic ulcer, seizure disorders, or cardiac arrhythmias. Levels may be affected by smoking cessation, fever, or medications like cimetidine, fluoroquinolones, and macrolides.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take this medication exactly as prescribed; do not crush or chew the sustained-release tablets.,Avoid taking with large amounts of caffeine (coffee, tea, soda) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, restlessness, insomnia, rapid heartbeat, or seizures.,Do not change brands or dosing schedule without consulting your provider.,Maintain consistent intake of food and avoid sudden changes in diet that may affect absorption.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOLAIR-SR vs AEROLATE JR, answered by our medical review team.
THEOLAIR-SR is a Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and antagonizing adenosine receptors.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOLAIR-SR and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOLAIR-SR is: Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/m L).. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOLAIR-SR and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOLAIR-SR is classified as Category C. Theophylline crosses the placenta. First trimester: No clear evidence of major malformations in human studies, but animal studies show some risk at high doses (skeletal variations). AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.